Yuyu Pharma Q1 2026 Consolidated Sales 35.5B Won, OP 4.3B Won; Strong Parent Growth YoY

Q1 2026 consolidated revenue 35.5B won (+8.4% YoY), operating profit 4.3B won (-1.8% YoY), net profit 3.35B won (+0.2% YoY)
Parent (separate) revenue 27.2B won (+22.9%), OP 4.96B won (+23.2%), net profit 3.96B won (+59.2%), showing strong growth
Consolidated OP decline due to weak performance of subsidiaries: Yuyu Healthcare (OP 0.13B, vs 0.73B) and Yuyu Medicals (loss 0.21B)
Key pipeline: BPH treatments YY-DUT and YY-DUT-Tam preparing for US/EU bioequivalence trials
Multiple generics and data-submission drugs approved in 2024-2025 (Tannamin, Senubela, etc.)
Dividend for 86th fiscal year 2.13B won unpaid as of March 2026
Debt ratio 27.1% (consolidated), maintaining stable financial structure
Partial early redemption of CBs (30th and 31st series); remaining balances 1.5B won and 10.3B won respectively